Search Results 861-870 of 16368 for monoclonal antibody
... monoclonal antibody escape mutation in a persistently infected, immunocompromised individual. Virus Evol. 2023; 9 (2):veac104 Epub 2022 Nov 05. View PubMed ...
Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ...
... monoclonal antibodies, fusion proteins, or CHO cell products. Participating Mayo Clinic locations. Study statuses change often. Please contact the study team ...
... monoclonal antibody * For Cohorts G, H, and I: Has symptomatic ascites or pleural effusion * For Cohort I: Has clinically active diverticulitis, intra ...
- Immunotherapy (monoclonal antibodies) =< 4 weeks prior to registration - Experimental agent in case of AML or TCL within 4 half-lives of the last dose of
Radioactive substances linked to monoclonal antibodies, such as 90-yttrium ibritumomab tiuxetan, can bind to cancer cells and give off radiation which may help ...
... antibody (ANCA) associated vasculitis using primary samples and/or patient derived xenograft models. Participation eligibility. Participant eligibility ...
Has had a prior monoclonal antibody within 4 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due ...
... monoclonal antibody or hypersensitivity to pembrolizumab or any of its excipients. Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks ...
... monoclonal antibody approved by the FDA for the treatment of relapsing MS, or (iii) rituximab. Qualifying DMTs include: dimethyl fumarate, diroximel ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Make your tax-deductible gift and be a part of the cutting-edge research and care that's changing medicine.